维普中文期刊产品整合服务

Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study

查看全文 作　　者：Gustavo Drugg [1,2]Hahn;Jean-Frederic [3]LeBlanc;Petra Anna [1,4]Golovics;Panu [1,5]Wetwittayakhlang;Abdulrahman [1]Qatomah;Anna [1]Wang;Levon [1]Boodaghians;Jeremy Liu Chen [6]Kiow;Maryam Al [1]Ali;Gary [1]Wild;Waqqas [1]Afif;Alain [1]Bitton;Peter Laszlo [1]Lakatos;Talat [1]Bessissow 高影响力作者 机构地区：[1]Division of Gastroenterology,IBD Center,McGill University Health Center,Montreal H3G 1A4,Quebec,Canada;[2]School of Medicine,Graduate Course Sciences in Gastroenterology and Hepatology,Universidade Federal do Rio Grande do Sul,Porto Alegre 90000-000,Brazil;[3]Division of Gastroenterology,McGill University Health Centre,Montreal H3G 1A4,Quebec,Canada;[4]Department of Gastroenterology,Hungarian Defense Forces,Medical Centre,Budapest 1134,Hungary;[5]Unit of Gastroenterology and Hepatology,Division of Internal Medicine,Faculty of Medicine,Prince of Songkla University,Songkhla 90110,Thailand;[6]Department of Gastroenterology,Centre Hospitalier de l’Universitede Montreal,Montreal H2X 3E4,Quebec,Canada高影响力机构 出　　处：《World Journal of Gastroenterology》索引2022年第28卷第33期,共11页高影响力期刊 摘　　要：BACKGROUND Biologic therapy resulted in a significant positive impact on the management of inflammatory bowel disease(IBD) however data on the efficacy and side effects of these therapies in the elderly is scant.AIM To evaluate retrospectively the drug sustainability, effectiveness, and safety of the biologic therapies in the elderly IBD population.METHODS Consecutive elderly(≥ 60 years old) IBD patients, treated with biologics [infliximab(IFX), adalimumab(ADAL), vedolizumab(VDZ), ustekinumab(UST)] followed at the McGill University Inflammatory Bowel Diseases Center were included between January 2000 and 2020.Efficacy was measured by clinical scores at 3, 6-9 and 12-18 mo after initiation of the biologic therapy. Patients completing induction therapy were included. Adverse events(AEs) or serious AE were collected during and within three months of stopping of the biologic therapy.RESULTS We identified a total of 147 elderly patients with IBD treated with biologicals during the study period, including 109 with Crohn’s disease and 38 with ulcerative colitis. Patients received the following biologicals: IFX(28.5%), ADAL(38.7%), VDZ(15.6%), UST(17%). The mean duration of biologic treatment was 157.5(SD = 148) wk. Parallel steroid therapy was given in 34% at baseline,19% at 3 mo, 16.3% at 6-9 mo and 6.5% at 12-18 mo. The remission rates at 3, 6-9 and 12-18 mo were not significantly different among biological therapies. Kaplan-Meyer analysis did not show statistical difference for drug sustainability(P = 0.195), time to adverse event(P = 0.158) or infection rates(P = 0.973) between the four biologics studied. The most common AEs that led to drug discontinuation were loss of response, infusion/injection reaction and infection.CONCLUSION Current biologics were not different regarding drug sustainability, effectiveness, and safety in the elderly IBD population. Therefore, we are not able to suggest a preferred sequencing order among biologicals. 关 键 词：Inflammatory bowel disease BIOLOGICS ELDERLY Efficacy SAFETY Adverse events
相关文献

参考文献(25)

引证文献(3)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费